Jonathan Biller

Chief Financial and Information Officer

Personal Data

Nationality
Netherlands

Year of Birth
1984

Dr. Frank Anderson, a native of the Netherlands, is the Head of Pharma Research and Early Development (pRED) at Hexion Pharmaceutical (Canada). He holds a Master’s and Doctorate in Biology, as well as an M.D., all from the University of Utrecht.

Dr. Anderson’s career began with post-doctoral research at Dana-Farber Cancer Institute and Harvard Medical School, followed by roles as Assistant Professor and then Professor and Chairman at the University of Utrecht. He went on to lead the Hubrecht Institute as Head Director and continued as a Professor in Molecular Genetics at the University of Utrecht.

His extensive career includes serving as President of the Royal Netherlands Academy of Sciences, Director of Research at the Princess Máxima Center for Pediatric Oncology, and Principal Investigator of a research group. He was also a Member of the Board of Directors at Hexion Pharmaceutical Holding Ltd.

Dr. Anderson is an esteemed member of numerous scientific advisory boards and has held significant roles in organizations such as the International Society for Stem Cell Research and the Francis Crick Institute. He has co-founded and advised several companies, including Surrozen and Xilis.

He is a member of various professional associations, including the Royal Netherlands Academy of Sciences and the National Academy of Sciences of the USA. Dr. Anderson’s distinguished career has earned him numerous awards, including the Spinoza Award, the Louis-Jeantet Prize for Medicine, and the Breakthrough Prize in Life Sciences.

Dr. Anderson's contributions to cancer research and molecular genetics are widely recognized and celebrated internationally.